Effect of S-Adenosyl Methionine Treatment on Recurrence After Curative Resection of Hepatocellular Carcinoma

A Randomized Controlled Study on the Effect of S-Adenosyl Methionine Treatment on Anti-tumor Recurrence After Curative Resection of Hepatocellular Carcinoma

Status

UNKNOWN

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02586285

Enrollment

300

Registered

2015-10-26

Start date

2015-06-30

Completion date

2017-12-31

Last updated

2016-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular Carcinoma

Keywords

S-Adenosyl Methionine, Recurrence

Brief summary

The aim of this study is to explore the effect of S-Adenosyl Methionine on recurrence after curative resection of Hepatocellular Carcinoma.

Detailed description

Hepatocellular carcinoma (HCC) is now a major health problem. Although the recent advances in treatment of HCC have significantly improved the prognosis of patients with HCC, the overall survival rate is still unsatisfactory; the 5-year survival rate is only 50-70% even after curative treatment such as hepatic resection and percutaneous radiofrequency ablation. One of the reasons for the poor prognosis of HCC is its high rate of recurrence.However,anti-relapse treatment remains a pressing work to do. In recent years, some study reported that S-Adenosyl Methionine had an impact on promoting apoptosis and inhibiting the growth on breast cancer, colon cancer,gastric cancer and liver cancer in vitro and vivo. In this study, we aim to examine whether S-Adenosyl Methionine have an effect on improving patients' recurrence after curative resection of Hepatocellular Carcinoma.

Interventions

DRUGS-Adenosyl Methionine

500mg-1000mg,iv,qd

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

* Male or female patients \> 18 years and \<=70 years of age * Patients preoperatively diagnosed of hepatocellular carcinoma according to the criteria of American Association for the Study of Liver Diseases(AASLD) * Within Milan criteria * Without or mild liver cirrhosis and the liver function is Child A class. * Without any other treatments such as TACE、PEI、PRFA before the surgery * No evidence for extrahepatic metastasis

Exclusion criteria

* Patients with macro tumor thrombus or extrahepatic metastasis. * Patients with apparent cardiac, pulmonary, cerebral and renal dysfunction. * Subjects accepting other trial drugs or participating in other clinical trials. * Patients refuse to join our trial. * Female with pregnancy or during the lactation period.

Design outcomes

Primary

Measure	Time frame
Time to tumor recurrence	5 years

Secondary

Measure	Time frame
Overall survival	5 years

Countries

China

Contacts

Primary ContactShen Feng, MD

shenfengdfgd@yahoo.com.cn0086-021-25070805

Backup ContactWang Kui, MD

wangkuiykl@163.com

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026